Sterling Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Sterling Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.93K	Sell	313 -331	-51%	-$2.36K	﹤0.01%	3003
2025 Q4	$4.64K	Buy	644 +5	+0.8%	+$40	﹤0.01%	2914
2025 Q3	$6.53K	Buy	639 +416	+187%	+$4.68K	﹤0.01%	2689
2025 Q2	$2.32K	Buy	223 +209	+1,493%	+$2.23K	﹤0.01%	2883
2025 Q1	$185	Hold	14	–	–	﹤0.01%	3092
2024 Q4	$251	Buy	14 +7	+100%	+$142	﹤0.01%	3102
2024 Q3	$113	Buy	+7	New	+$109	﹤0.01%	3183

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Capital Management's RNAC Position: Q1 2026 in Review

Sterling Capital Management reduced its Cartesian Therapeutics (RNAC) stake by 51% in Q1 2026, selling an estimated $2.36K and leaving 313 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #3003.

Sterling Capital Management first reported a position in RNAC in Q3 2024 and has held it in 7 quarters since. The position peaked at $6.53K in Q3 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Sterling Capital Management held 313 shares of Cartesian Therapeutics worth $1.93K as of Q1 2026.
Sterling Capital Management sold 331 Cartesian Therapeutics shares in Q1 2026, an estimated $2.36K.
Cartesian Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #3003 holding.
Sterling Capital Management first reported a position in Cartesian Therapeutics in Q3 2024 and has held it in 7 quarters since.
Sterling Capital Management's Cartesian Therapeutics position peaked at $6.53K in Q3 2025.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.